AJR F and L Medical Products: Radiation Protection & More
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by de Jong, P. A.
Right arrow Articles by de Klerk, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Jong, P. A.
Right arrow Articles by de Klerk, J. M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Hotlight (NEW!)
Right arrow
What's Hotlight?
DOI:10.2214/AJR.08.1160
AJR 2009; 192:745-753
© American Roentgen Ray Society


Original Research

CT and 18F-FDG PET for Noninvasive Detection of Splenic Involvement in Patients with Malignant Lymphoma

Pim A. de Jong1,2, Henriette M. Quarles van Ufford1,2, Henk-Jan Baarslag1, Marie J. de Haas1, Shulamiet H. Wittebol3, Lorentz G. Quekel1 and John M. de Klerk1

1 Department of Radiology and Nuclear Medicine, Meander Medisch Centrum, Lichtenberg, Amersfoort, The Netherlands.
2 Present address: Department of Radiology, University Medical Center Utrecht, HP E.01.132, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
3 Department of Internal Medicine, Meander Medisch Centrum, Lichtenberg, Amersfoort, The Netherlands.

OBJECTIVE. The purpose of this study was to determine the sensitivity and specificity of 18F-FDG PET, CT, and combined PET/CT in the detection of splenic involvement at initial staging of lymphoma.

MATERIALS AND METHODS. A retrospective longitudinal analysis was performed on the records of 111 patients with proven lymphoma who had undergone PET and CT before and after treatment. CT scans were evaluated independently by two radiologists, and PET scans by two nuclear medicine physicians. Abnormal CT findings were defined as low-attenuation nodules or a splenic index greater than 725 cm3 (> 2 SDs above the mean in 100 controls). An abnormal PET finding was defined as splenic uptake greater than hepatic uptake. True splenic involvement was defined retrospectively on the basis of the treatment response assessed with criteria revised in the International Harmonization Project on lymphoma. Observer agreement and sensitivity and specificity values were calculated.

RESULTS. Observer agreement for CT splenic index and PET findings was good. For initial splenic staging, the sensitivity and specificity of CT, PET, and PET/CT were 91% and 96%, 75% and 99%, and 100% and 95%.

CONCLUSION. For initial staging of splenic involvement in malignant lymphoma, the sensitivity and specificity of PET/CT can reach 100% and 95%. The sensitivity of the combined approach is higher than that of either technique alone.

Keywords: CT • FDG PET • lymphoma • sensitivity • specificity • splenic index • splenic involvement


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the American Roentgen Ray Society.